Vaccine comprising AMB A 1 peptides for use in the treatment of ragweed allergy
The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
1. A method of treating allergy to ragweed, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising the polypeptides which consist of the following sequences:
(a) RDLLENGAIFLPSG (SEQ ID NO. 9; RGW03B),
(b) GMIKSNDGPPI (SEQ ID NO. 2; RGW01),
(c) SAGMIPAEPGEA (SEQ ID NO: 11; RGW04A),
(d) GSSQIWIDHSSLSKS (SEQ ID NO: 4; RGW02),
(e) KEGTLRFAAAQNRP (SEQ ID NO:12; RGW05),
(f) AINNDKTIDGRGAKVE (SEQ ID NO:15; RGW06A), and
(g) KGEAAIKLTSSAGVLSKK (SEQ ID NO: 20; RGW07D).
2. The method of claim 1 , wherein said subject is a human.
3. The method of claim 1 , wherein said subject is ragweed allergic.
4. The method of claim 1 , wherein said subject:
is sensitised to Amb a 1;
has a family history of allergy to ragweed; or
displays symptoms of allergy when exposed to ragweed.
5. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
6. The method of claim 1 , wherein said composition is provided as an injectable solution, suspension or emulsion.
7. The method of claim 1 , wherein said composition is formulated for administration parenterally, subcutaneously, intradermally or transdermally.